DDInter667 DDInter1694
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Erlotinib {u} (Compound) resembles {v} (Compound) Vandetanib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Erlotinib {u} (Compound) treats {v} (Disease) kidney cancer
Erlotinib {u} (Compound) binds {v} (Gene) CYP1A2
Erlotinib {u} (Compound) upregulates {v} (Gene) IL1B
Erlotinib {u} (Compound) downregulates {v} (Gene) COX8A
Erlotinib {u} (Compound) causes {v} (Side Effect) Drug interaction
Erlotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Erlotinib (Compound) resembles Vandetanib (Compound)
Erlotinib (Compound) resembles Gefitinib (Compound)
Erlotinib (Compound) treats kidney cancer (Disease)
Erlotinib (Compound) binds CYP1A2 (Gene)
Erlotinib (Compound) upregulates IL1B (Gene)
Erlotinib (Compound) downregulates COX8A (Gene)
Erlotinib (Compound) causes Drug interaction (Side Effect)
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine